Last reviewed · How we verify

Pentacel®: DTaP-IPV/Hib combined

Sanofi Pasteur, a Sanofi Company · Phase 3 active Biologic

Pentacel®: DTaP-IPV/Hib combined is a vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Protection against diphtheria, tetanus, pertussis, poliovirus, and Haemophilus influenzae type b in children, Prevention of invasive disease caused by Haemophilus influenzae type b. Also known as: Pentacel®.

Pentacel stimulates the body's immune response to produce antibodies against diphtheria, tetanus, pertussis, poliovirus, and Haemophilus influenzae type b.

Pentacel stimulates the body's immune response to produce antibodies against diphtheria, tetanus, pertussis, poliovirus, and Haemophilus influenzae type b. Used for Protection against diphtheria, tetanus, pertussis, poliovirus, and Haemophilus influenzae type b in children, Prevention of invasive disease caused by Haemophilus influenzae type b.

At a glance

Generic namePentacel®: DTaP-IPV/Hib combined
Also known asPentacel®
SponsorSanofi Pasteur, a Sanofi Company
Drug classvaccine
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

This is achieved through the administration of inactivated or killed pathogens, which triggers an immune response and the production of antibodies. The antibodies then provide long-term protection against future infections.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Pentacel®: DTaP-IPV/Hib combined

What is Pentacel®: DTaP-IPV/Hib combined?

Pentacel®: DTaP-IPV/Hib combined is a vaccine drug developed by Sanofi Pasteur, a Sanofi Company, indicated for Protection against diphtheria, tetanus, pertussis, poliovirus, and Haemophilus influenzae type b in children, Prevention of invasive disease caused by Haemophilus influenzae type b.

How does Pentacel®: DTaP-IPV/Hib combined work?

Pentacel stimulates the body's immune response to produce antibodies against diphtheria, tetanus, pertussis, poliovirus, and Haemophilus influenzae type b.

What is Pentacel®: DTaP-IPV/Hib combined used for?

Pentacel®: DTaP-IPV/Hib combined is indicated for Protection against diphtheria, tetanus, pertussis, poliovirus, and Haemophilus influenzae type b in children, Prevention of invasive disease caused by Haemophilus influenzae type b.

Who makes Pentacel®: DTaP-IPV/Hib combined?

Pentacel®: DTaP-IPV/Hib combined is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).

Is Pentacel®: DTaP-IPV/Hib combined also known as anything else?

Pentacel®: DTaP-IPV/Hib combined is also known as Pentacel®.

What drug class is Pentacel®: DTaP-IPV/Hib combined in?

Pentacel®: DTaP-IPV/Hib combined belongs to the vaccine class. See all vaccine drugs at /class/vaccine.

What development phase is Pentacel®: DTaP-IPV/Hib combined in?

Pentacel®: DTaP-IPV/Hib combined is in Phase 3.

What are the side effects of Pentacel®: DTaP-IPV/Hib combined?

Common side effects of Pentacel®: DTaP-IPV/Hib combined include Pain, redness, or swelling at the injection site, Fever, Irritability.

Related